US Patent 6,756,033: What Is Claimed, How Broad the Scope Is, and Where the Landscape Stands

US 6,756,033 claims inhalation delivery of “benzindene prostaglandin” compounds using sub-10 micrometer aerosol droplets (liquid) or sub-10 micrometer powder particles (dry powder). The core limitation is the inhaled form factor (droplet/particle size under 10 µm) coupled to therapeutic delivery by inhalation. Dependent claims narrow to a specific compound embodiment (9-deoxy-2′,9-alpha-methano-3-oxa-4,5,6-trinor3,7-(1′3′-interphenylene)-1 3,14-dihydro-prostaglandin F1), sustained release formulations, human use, and “no effect on heart rate.”

What is the invention scope in one line?

It is a delivery method claim: administering benzindene prostaglandin by inhalation using particles or droplets smaller than 10 micrometers, with optional constraints for sustained release, heart-rate non-effect, human administration, and a named benzindene prostaglandin species.

What do the claims cover, claim by claim?

Independent claim set: 2 delivery formats

Claim 1 (liquid inhalation; droplets)

Method of delivering a therapeutically effective amount of a “benzindene prostaglandin” to a mammal
Administration: by inhalation
Form factor: droplets measuring less than 10 micrometers in diameter
Composition: droplets comprise therapeutically effective amount of the benzindene prostaglandin

Claim 6 (dry powder inhalation; particles)

Same overall method structure
Administration: by inhalation
Form factor: powder particles measuring less than 10 micrometers in diameter
Composition: particles comprise therapeutically effective amount of the benzindene prostaglandin

Business implication: the patent is not limited to one device class (e.g., nebulizer vs DPI) as long as the formulation achieves the sub-10 µm droplet/particle size limitation. Enforcement risk therefore tracks product aerosol or aerosolizable particle-size distribution in the delivered inhaled cloud, not only the labeled formulation type.

Dependent narrowing points

Claim 2 (specific compound + liquid carrier)

Adds: “benzindene prostaglandin is 9-deoxy-2′,9-alpha-methano-3-oxa-4,5,6-trinor3,7-(1′3′-interphenylene)-1 3,14-dihydro-prostaglandin F1”
Adds: suitable pharmacologically acceptable liquid carrier
Keeps: inhalation + droplets < 10 µm

Claim 3 (human use)

Keeps: claim 1 scope
Adds: mammal is human

Claim 4 (sustained release)

Keeps: claim 1 scope
Adds: sustained release form

Claim 5 (heart rate non-effect)

Keeps: claim 1 scope
Adds: administering benzindene prostaglandin has no effect on heart rate

Claim 7 (specific compound in powder format)

Keeps: claim 6 scope
Adds: benzindene prostaglandin is UT-15

Claim 8 (human use in powder format)

Keeps: claim 6 scope
Adds: mammal is human

Claim 9 (sustained release in powder format)

Keeps: claim 6 scope
Adds: sustained release form

Claim 10 (heart rate non-effect in powder format)

Keeps: claim 6 scope
Adds: no effect on heart rate

How broad is the claim scope? (Key limitation-by-limitation analysis)

1) The compound class: “benzindene prostaglandin”

The independent claims are written to a genus: any “benzindene prostaglandin” that can be delivered therapeutically by inhalation in the required size form. Without a built-in structural definition in the provided text, the effective breadth depends on the patent’s internal definition and how “benzindene prostaglandin” is construed in prosecution and claim construction. Practically, this means freedom-to-operate risk depends on whether the candidate API falls within that class term.

2) The delivery route: “administering … by inhalation”

This is a method claim requiring inhalation administration to the mammal. It covers both:

nebulized aerosol delivery of liquid formulations, and
dry powder inhaler delivery of powder formulations, as long as the delivered form meets the size threshold.

3) The size threshold: “less than 10 micrometers”

This is the strongest technical delimiter in both independent claims.

Critical nuance: enforcement often turns on how “droplets measuring less than 10 micrometers in diameter” and “particles measuring less than 10 micrometers in diameter” are interpreted in relation to measurement methods (e.g., Dv50, MMAD, or percent volume under 10 µm). The provided claim language sets a hard cutoff, but real-world infringement analysis will hinge on the formulation’s size distribution and the claim construction of “measuring less than 10 micrometers.”

Practical takeaway: if a product targets a similar prostaglandin family but uses larger droplets/particles (or a distribution that does not meet the “less than 10 µm” requirement in the relevant measurement framework), it may avoid the core independent claims.

4) Therapeutically effective amount

Both independent claims require a therapeutically effective amount. This is typically satisfied if the product is labeled for therapeutic use, but method patents can be attacked if clinical dosing does not meet claimed “therapeutically effective” performance. The claim text you provided does not define potency or a specific efficacy endpoint.

5) Dependent modifiers: sustained release, human use, and “no effect on heart rate”

These add constraints that can be used as design-around levers.

Sustained release (Claims 4 and 9): Narrows to formulations that behave as sustained release. A product designed as immediate-release could fall outside those dependent claims while still potentially meeting the independent claims.
No effect on heart rate (Claims 5 and 10): This is a functional limitation. It can narrow the claim scope meaningfully in practice, but it also invites clinical and protocol-specific arguments. If a product shows any measurable heart rate effect in a relevant population, it can become a dispute point for infringement or invalidity.
Human (Claims 3 and 8): Narrows patient population. If a product is intended for animals but not humans, dependent claims may not read on it, while independent claims may still be asserted unless the claim term “mammal” is construed to cover the target use.

6) Specific named compounds (Claim 2 and Claim 7)

Claim 2 explicitly recites a named benzindene prostaglandin structure (9-deoxy-…-dihydro-prostaglandin F1)
Claim 7 recites “UT-15” These dependent claims anchor enforceability for specific APIs even if the genus term is contested.

What is the practical infringement “hit map” for a competing inhalation product?

Below is a structured way to map product attributes to claim elements.

Element match matrix

Claim	Form	Size limit	Compound genus/specific	Patient	Extra constraints
1	Liquid droplets	<10 µm droplets	Any benzindene prostaglandin	Any mammal	None beyond claim 1
2	Liquid droplets	<10 µm droplets	Specific benzindene prostaglandin (named) + liquid carrier	Any mammal	Specific API + carrier
3	Liquid droplets	<10 µm droplets	Any benzindene prostaglandin	Human	Human only
4	Liquid droplets	<10 µm droplets	Any benzindene prostaglandin	Any mammal	Sustained release
5	Liquid droplets	<10 µm droplets	Any benzindene prostaglandin	Any mammal	No heart-rate effect
6	Powder particles	<10 µm particles	Any benzindene prostaglandin	Any mammal	None beyond claim 6
7	Powder particles	<10 µm particles	UT-15	Any mammal	Specific API
8	Powder particles	<10 µm particles	Any benzindene prostaglandin	Human	Human only
9	Powder particles	<10 µm particles	Any benzindene prostaglandin	Any mammal	Sustained release
10	Powder particles	<10 µm particles	Any benzindene prostaglandin	Any mammal	No heart-rate effect

High-risk configurations

Any inhaled benzindene prostaglandin product whose aerosol droplet size or powder particle size distribution satisfies <10 µm delivered-measurement interpretation.
Any product using UT-15 delivered as inhalable particles <10 µm (powder path) or the named compound as inhaled droplets <10 µm (liquid path).
Any product positioned as sustained release while also achieving <10 µm droplets/particles.

Lower-risk levers

Formulation design that does not achieve <10 µm droplets/particles under the relevant measurement framework.
Immediate-release formulations (to avoid sustained release-dependent claims), though independent claims remain a risk.
Evidence-driven positioning around heart-rate effects (to potentially avoid dependent claims 5 and 10), though independent claims still stand.

What is the patent landscape implication? (Where this fits in a typical prostaglandin inhalation strategy)

This patent is method-formulation focused

US 6,756,033 is drafted around the delivery mechanism: inhalation + sub-10 µm droplet/particle size. That places it in the intersection of:

prostaglandin medicinal chemistry IP (API genus and specific analogs),
formulation/device delivery IP (aerosol and DPI particle-size engineering),
and possibly pharmacology IP (heart-rate effect characterization and sustained release design).

Expected landscape dynamics

For companies developing inhaled prostaglandin analogs, this kind of claim typically forces a landscape workflow with three parallel tracks:

API scope mapping: does the candidate API fall within “benzindene prostaglandin”?
Physical property mapping: do delivered droplets/particles meet the “<10 µm” limitation?
Clinical behavior mapping: sustained release status and heart-rate effect profiles for dependent claim coverage.

Claim drafting tells you where prior art was likely concentrated

The tight physical size delimiter implies that prior art likely existed for prostaglandin inhalation but with different particle sizes (or different delivery media), making sub-10 µm a key novelty axis. The dependent “no effect on heart rate” implies that earlier candidates may have had cardiovascular side effects and that the patentee worked to differentiate by clinical safety.

Key takeaways

US 6,756,033 covers inhalation delivery of “benzindene prostaglandin” via sub-10 µm droplets (liquid) or sub-10 µm powder particles (dry powder).
The independent claims are broad on compound genus and mammal identity, with the main limiting feature being aerosol/particle size under 10 µm.
Dependent claims narrow by specific benzindene prostaglandin species (named compound and UT-15), sustained release, human use, and no heart-rate effect.
For a freedom-to-operate screen, the decisive technical question is whether the product’s delivered size distribution meets the claim’s <10 µm requirement under the relevant measurement framework.
“Sustained release” and “no heart rate” are additional constraints that may reduce dependent claim risk but do not avoid independent claim exposure if the sub-10 µm inhalation delivery is met.

FAQs

1) Does US 6,756,033 require a specific benzindene prostaglandin structure?

No for the independent claims. Claims 1 and 6 require a “benzindene prostaglandin” genus. Specific structures appear in dependent claims 2 and 7.

2) Is the patent limited to nebulizers or inhalers?

No. It covers inhalation delivery in both liquid (droplets) and powder (particles) formats, as long as the droplet or particle size is less than 10 µm.

3) Can a product avoid the patent by making a sustained-release formulation?

Sustained release increases dependent claim exposure (claims 4 and 9). It does not avoid independent claims 1 and 6 if sub-10 µm inhalation is achieved.

4) Does “no effect on heart rate” matter for infringement?

Yes for dependent claims 5 and 10. If the product shows any relevant heart-rate effect under applicable study conditions, it may be used to argue non-read across those dependent claims. Independent claims remain separate.

5) What is the most important technical parameter to evaluate?

The delivered aerosol droplet size or powder particle size: <10 micrometers as required by claims 1 and 6.

References (APA)

[1] Provided claim text for US 6,756,033 (claims 1-10) in the prompt.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	245979	⤷ Start Trial
Australia	4082700	⤷ Start Trial
Canada	2365890	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,756,033

Summary for Patent: 6,756,033